Jun Yang1, Frederick K Korley2, Min Dai3, Allen D Everett4. 1. Department of Pediatrics, Division of Pediatric Cardiology, Johns Hopkins University, School of Medicine, Baltimore, MD, United States. 2. Department of Emergency Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, United States. 3. Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, MD, United States. 4. Department of Pediatrics, Division of Pediatric Cardiology, Johns Hopkins University, School of Medicine, Baltimore, MD, United States. Electronic address: aeveret3@jhmi.edu.
Abstract
OBJECTIVES: Neurogranin (NRGN) is a small neuronal protein that plays an important role in synaptic signaling by regulating calmodulin (CaM) availability. In this study, we developed an ELISA to measure NRGN quantitatively in serum samples from a cohort of acute traumatic brain injury (TBI) patients and a non-TBI control cohort, and explored the potential value of NRGN as a circulating biomarker for TBI. DESIGN AND METHODS: Recombinant His-NRGN protein was used to develop mouse monoclonal capture and rabbit polyclonal detection antibodies, and they were used to develop a sandwich ELISA. After validation, we used this ELISA to measure serum samples from a cohort of typical adult acute TBI patients (N=76 TBI cases) and non-TBI control patients (N=150 controls). RESULTS: The NRGN ELISA lower limit of detection was 0.055ng/mL, lower limit of quantification was 0.2ng/mL, and interassay CVs were ≤10.7%. The average recovery was 99.9% (range from 97.2-102%). Serum NRGN concentrations in TBI cases were significantly higher than in controls (median values were 0.18ng/mL vs. 0.02ng/mL, p<0.0001), but did not discriminate TBI cases with intracranial hemorrhage (p=0.09). CONCLUSIONS: We have developed a highly sensitive and reproducible ELISA for measuring circulating NRGN in blood samples. Serum NRGN concentrations in acute TBI patients were significantly higher than in controls, indicating that NRGN could have utility as a circulating biomarker for acute TBI. This report provides evidence to support larger and controlled TBI clinical studies for NRGN validation and prediction of outcomes.
OBJECTIVES:Neurogranin (NRGN) is a small neuronal protein that plays an important role in synaptic signaling by regulating calmodulin (CaM) availability. In this study, we developed an ELISA to measure NRGN quantitatively in serum samples from a cohort of acute traumatic brain injury (TBI) patients and a non-TBI control cohort, and explored the potential value of NRGN as a circulating biomarker for TBI. DESIGN AND METHODS: Recombinant His-NRGN protein was used to develop mouse monoclonal capture and rabbit polyclonal detection antibodies, and they were used to develop a sandwich ELISA. After validation, we used this ELISA to measure serum samples from a cohort of typical adult acute TBI patients (N=76 TBI cases) and non-TBI control patients (N=150 controls). RESULTS: The NRGN ELISA lower limit of detection was 0.055ng/mL, lower limit of quantification was 0.2ng/mL, and interassay CVs were ≤10.7%. The average recovery was 99.9% (range from 97.2-102%). Serum NRGN concentrations in TBI cases were significantly higher than in controls (median values were 0.18ng/mL vs. 0.02ng/mL, p<0.0001), but did not discriminate TBI cases with intracranial hemorrhage (p=0.09). CONCLUSIONS: We have developed a highly sensitive and reproducible ELISA for measuring circulating NRGN in blood samples. Serum NRGN concentrations in acute TBI patients were significantly higher than in controls, indicating that NRGN could have utility as a circulating biomarker for acute TBI. This report provides evidence to support larger and controlled TBI clinical studies for NRGN validation and prediction of outcomes.
Authors: Frederick K Korley; Steven P Schulman; Lori J Sokoll; Andrew P DeFilippis; Andrew I Stolbach; Jamil D Bayram; Mustapha O Saheed; Rodney Omron; Christopher Fernandez; Albert Lwin; Stephen S Cai; Wendy S Post; Allan S Jaffe Journal: Acad Emerg Med Date: 2014-08-11 Impact factor: 3.451
Authors: Zhicheng Jin; Zongming Fu; Jun Yang; Juan Troncosco; Allen D Everett; Jennifer E Van Eyk Journal: Proteomics Date: 2013-08-07 Impact factor: 3.984
Authors: Matthew E Peters; Vani Rao; Kathleen T Bechtold; Durga Roy; Haris I Sair; Jeannie-Marie Leoutsakos; Ramon Diaz-Arrastia; Robert D Stevens; D Scott Batty; Hayley Falk; Christopher Fernandez; Uju Ofoche; Alexandra Vassila; Anna J Hall; Braden Anderson; Edward Bessman; Constantine G Lyketsos; Allen D Everett; Jennifer Van Eyk; Frederick K Korley Journal: Brain Inj Date: 2017-01-31 Impact factor: 2.311
Authors: Brian K Kwon; Ona Bloom; Ina-Beate Wanner; Armin Curt; Jan M Schwab; James Fawcett; Kevin K Wang Journal: Spinal Cord Date: 2019-07-04 Impact factor: 2.772
Authors: Marina Betancor; Sonia Pérez-Lázaro; Alicia Otero; Belén Marín; Inmaculada Martín-Burriel; Kaj Blennow; Juan José Badiola; Henrik Zetterberg; Rosa Bolea Journal: Int J Mol Sci Date: 2022-06-28 Impact factor: 6.208
Authors: Sandra Brooks; Barbara D Friedes; Frances Northington; Ernest Graham; Aylin Tekes; Vera J Burton; Gwendolyn Gerner; Jie Zhu; Raul Chavez-Valdez; Dhananjay Vaidya; Allen D Everett Journal: Pediatr Res Date: 2021-12-18 Impact factor: 3.953
Authors: W Frank Peacock; Timothy E Van Meter; Nazanin Mirshahi; Kyle Ferber; Robert Gerwien; Vani Rao; Haris Iqbal Sair; Ramon Diaz-Arrastia; Frederick K Korley Journal: Front Neurol Date: 2017-11-30 Impact factor: 4.003
Authors: Ann De Vos; Maria Bjerke; Raf Brouns; Naomi De Roeck; Dirk Jacobs; Lien Van den Abbeele; Kaat Guldolf; Henrik Zetterberg; Kaj Blennow; Sebastiaan Engelborghs; Eugeen Vanmechelen Journal: BMC Neurol Date: 2017-08-30 Impact factor: 2.474